Large gap with delayed quotes
|
Last quote
12/26/2024 -
20:00:00
|
Bid
12/27/2024 -
04:05:47
|
Bid Volume |
Ask
- -
-
|
Ask Volume |
|---|---|---|---|---|
|
242.50
-0.75
(
-0.31% )
|
100.86
|
100 |
-
|
- |
Analysis date: 24.12.2024
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 05.11.2024.
Interest
Weak
Weak
Weak interest since 20.12.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 01.11.2024 at a price of 273.91.
Evaluation
Strongly undervalued
Strongly undervalued
Based on its growth potential and our own criteria, at its current price the stock is strongly undervalued.
MT Tech Trend
Negative
Negative
The forty day Medium Term Technical Trend is negative since 05.11.2024. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is
4wk Rel Perf
-3.96%
-3.96%
The four week relative underperformance versus SP500 is 3.96%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 15.11.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.26%.
Mkt Cap in $bn
31.25
31.25
With a market capitalization >$8bn, ALNYLAM PHARMACEUTICALS is considered a large-cap stock.
G/PE Ratio
1.55
1.55
A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio higher than 1.5 indicates that the stock's price presents a discount to growth >40% in this case.
LT P/E
71.54
71.54
The estimated PE is for the year 2026.
LT Growth
110.89%
110.89%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
22
22
Over the last seven weeks, an average of 22 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
72
72
For 1% of index variation, the stock varies on average by 0.72%.
Correlation
0.14
0.14
Stock movements are totally independent of index variations.
Value at Risk
52.37
52.37
The value at risk is estimated at USD 52.37. The risk is therefore 21.53%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
13.12.2006
13.12.2006